Logo
faq question Joey Med

CagriSema at Lower Doses in 2026: New REDEFINE 9 Results Show 21% Weight Loss With Less Medication

MD Telehealth Platform LLC DBA Joey Med is committed to protecting your health information in compliance with HIPAA regulations.
By Joey Med
5 min read
Published:
CagriSema's REDEFINE 9 trial showed about 21% average weight loss at doses below the maximum — what the new results mean for side effects, access, and your treatment options.

CagriSema's REDEFINE 9 trial showed about 21% average weight loss at doses below the maximum — what the new results mean for side effects, access, and your treatment options.

Overview

Novo Nordisk closed out ObesityWeek 2026 in Washington, DC with a result that could change how its next big weight loss drug is actually used. In the phase 3 REDEFINE 9 trial, presented on November 14 and published simultaneously in The Lancet Diabetes & Endocrinology, CagriSema produced roughly 21% average weight loss at doses well below the maximum studied so far. For patients, that raises a practical question worth understanding before this medication reaches pharmacies: if less drug delivers nearly the same result, what does that mean for side effects, flexibility, and eventually cost?

What the REDEFINE 9 trial found

CagriSema is a once-weekly injection that combines two medications in one pen: semaglutide (the GLP-1 found in Wegovy and Ozempic) and cagrilintide (a long-acting amylin analog that adds a second, complementary fullness signal). Every earlier phase 3 readout in the REDEFINE program used the maximum 2.4 mg/2.4 mg dose. REDEFINE 9 is the first phase 3 weight-management trial to test CagriSema below that ceiling.

Over 68 weeks, adults with overweight or obesity (average starting weight around 109.5 kg, or roughly 240 lbs) taking the 1.0 mg/1.0 mg dose lost an estimated average of 21.0% of their body weight, and those on 1.7 mg/1.7 mg lost 20.7%, compared with 2.0% on placebo, assuming participants stayed on treatment. Under the more conservative analysis that counts everyone regardless of whether they stopped, average losses were 18.6% and 19.4% versus placebo — still a difference of roughly 14 percentage points.

The responder numbers tell the same story: 87.7% of patients on the 1.0 mg dose and 92.8% on the 1.7 mg dose lost at least 5% of their body weight, versus 41.1% on placebo. Both doses also beat placebo on waist circumference, with reductions of about 17 cm reported in each CagriSema arm.

Why lower doses matter for real patients

Trial headlines usually chase the biggest number. This one matters for the opposite reason.

First, tolerability. The most common side effects in REDEFINE 9 were gastrointestinal — nausea, vomiting, constipation, diarrhea — and mostly mild to moderate, consistent with what GLP-1 users already know. Notably, only 2.9% of patients on the 1.7 mg dose and 4.9% on the 1.0 mg dose stopped treatment because of adverse events — the latter no higher than placebo, where 4.9% also discontinued. Dose is one of the biggest drivers of GI side effects across this drug class, so a lower maintenance dose that preserves most of the benefit could keep more people on treatment long enough to see results.

Second, flexibility. If regulators eventually include lower maintenance doses in the label, providers would have more room to individualize: not every patient needs, or tolerates, the maximum dose. Many patients on today's GLP-1s already plateau at middle doses with their provider's guidance.

Third, supply and cost. Lower-dose pens use less active ingredient. Novo Nordisk has not announced CagriSema pricing, so any dollar figure would be speculation — but a drug that works at lower doses is generally easier to manufacture at scale, which matters in a class that has repeatedly run into shortages.

One important caveat: REDEFINE 9 was not designed to compare the two doses against each other, so the nearly identical results do not prove the doses are interchangeable. That decision will sit with the FDA label and, ultimately, with prescribers.

How it compares to the full dose and today's options

In REDEFINE 1, the pivotal 3,417-person trial, the full 2.4 mg/2.4 mg dose produced 22.7% average weight loss over the same 68 weeks, versus 2.3% with placebo. So the lower doses in REDEFINE 9 landed within about two percentage points of the maximum dose — a remarkably small drop-off for a 30–60% reduction in medication.

For context, the semaglutide-only arm of REDEFINE 1 (equivalent to Wegovy 2.4 mg) delivered 16.1% average weight loss. Even at its lowest tested dose, CagriSema outperformed that benchmark in these trials, though cross-arm comparisons should always be read cautiously because trial populations differ.

Today, patients deciding on treatment are choosing among semaglutide, tirzepatide, and the new oral options. CagriSema's results slot above semaglutide and in the same conversation as tirzepatide, which remains one of the most effective options currently available by prescription.

When could you actually get CagriSema?

CagriSema is still investigational. Novo Nordisk submitted its FDA application in December 2025, and a decision is expected soon — we covered the timeline in detail in our earlier CagriSema update. If approved, a commercial launch is widely expected in 2027. The REDEFINE 9 data arriving now, just ahead of the decision, gives the FDA a fuller dosing picture to consider — though whether lower maintenance doses make it into the initial label remains to be seen.

Until then, no pharmacy, telehealth platform, or clinic can legitimately offer CagriSema, and patients should be wary of anyone claiming otherwise — the same caution that applies to unapproved retatrutide sold online.

Side effects and who should talk to a doctor first

Like other GLP-1-based medications, CagriSema's main side effects are gastrointestinal, typically worst during dose escalation and improving over time. GLP-1-class drugs are generally not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, a history of pancreatitis, or during pregnancy. Screening for these factors — plus a review of your medications, labs, and health history — is exactly why treatment decisions belong with a licensed provider, not a checkout page. Weight loss results also vary from person to person; trial averages are not a guarantee.

How to get started with JoeyMed

You don't need to wait for next year's drug to start making progress now. JoeyMed's licensed providers prescribe today's proven GLP-1-based treatments, including high-dose tirzepatide programs, when clinically appropriate — with anti-nausea support available to help you stay on track through dose escalation. Start with a free online visit at joeymed.com/weight-loss: share your health history, review your options with a provider, and if you qualify, medication ships discreetly to your door. And when CagriSema does arrive, we'll break down exactly how it fits alongside the options you have today.

CagriSema at Lower Doses in 2026: New REDEFINE 9 Results Show 21% Weight Loss With Less Medication | Joey Med Blog – Joey Med | GLP-1 Telehealth Tampa FL